Researchers Differentiate MIS-C From Severe COVID-19 in Children
TUESDAY, March 9, 2021 -- Patterns of clinical presentation and organ involvement may distinguish between children with multisystem inflammatory syndrome in children (MIS-C) and severe acute COVID-19, according to a study published online Feb. 24 in the Journal of the American Medical Association.
Leora R. Feldstein, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues compared clinical characteristics and outcomes of children and adolescents with MIS-C versus those with severe COVID-19. The analysis included a case series of 1,116 patients aged younger than 21 years hospitalized between March 15 and Oct. 31, 2020 (with follow-up through Jan. 5, 2021) at 66 U.S. hospitals in 31 states.
The researchers found that 48 percent of patients were diagnosed with MIS-C and 52 percent were diagnosed with COVID-19. Compared with patients with COVID-19, patients with MIS-C were more likely to be 6 to 12 years old (40.8 versus 19.4 percent; adjusted risk ratios [aRR], 1.51 versus 0 to 5 years) and non-Hispanic Black (32.3 versus 21.5 percent; aRR, 1.43 versus White). Additionally, patients with MIS-C were more likely than patients with COVID-19 to have cardiorespiratory involvement (aRR, 2.99), cardiovascular involvement without respiratory involvement (aRR, 2.49), and mucocutaneous involvement without cardiorespiratory involvement (aRR, 2.29). A higher neutrophil-to-lymphocyte ratio, higher C-reactive protein level, and lower platelet count were seen among patients with MIS-C. Among patients with MIS-C who had reduced left ventricular systolic function (34.2 percent) and coronary artery aneurysm (13.4 percent), these conditions normalized within 30 days in an estimated 91.0 and 79.1 percent, respectively.
"MIS-C was distinguished by certain demographic features and clinical presentations, including being aged 6 to 12 years, being of non-Hispanic Black race, having severe cardiovascular or mucocutaneous involvement, and having more extreme inflammation," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: March 2021
Further Support and Information on COVID-19
Read this next
MONDAY, April 19, 2021 -- The official global COVID-19 death toll surpassed 3 million this weekend, according to Johns Hopkins University data. But the actual number of people...
MONDAY, April 19, 2021 -- Moderna says a third booster shot for its two-dose COVID-19 vaccine will be available in the United States by the fall. The announcement was made by...
MONDAY, April 19, 2021 -- An indefinite extension on wearing masks and social distancing in all businesses is being considered by the administrator of the Oregon Department of...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.